The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Abstract
PURPOSE: To provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) with driver alterations. A guideline update for systemic therapy for patients with stage IV NSCLC without driver alterations was published separately. METHODS: The American Society of Clinical Oncology and Ontario Health (Cancer Care Ontario) NSCLC Expert Panel updated recommendations based on a systematic review of randomized controlled trials (RCTs) from December 2015 to January 2020 and meeting abstracts from ASCO 2020. RESULTS: This guideline update reflects changes in evidence since the previous update. Twenty-seven RCTs, 26 observational studies, and one meta-analysis provide the evidence base (total 54). Outcomes of interest included efficacy and safety. Additional literature suggested by the Expert Panel is discussed. RECOMMENDATIONS: All patients with nonsquamous NSCLC should have the results of testing for potentially targetable mutations (alterations) before implementing therapy for advanced lung cancer, regardless of smoking status recommendations, when possible, following other existing high-quality testing guidelines. Most patients should receive targeted therapy for these alterations: Targeted therapies against ROS-1 fusions, BRAF V600e mutations, RET fusions, MET exon 14 skipping mutations, and NTRK fusions should be offered to patients, either as initial or second-line therapy when not given in the first-line setting. New or revised recommendations include the following: Osimertinib is the optimal first-line treatment for patients with activating epidermal growth factor receptor mutations (exon 19 deletion, exon 21 L858R, and exon 20 T790M); alectinib or brigatinib is the optimal first-line treatment for patients with anaplastic lymphoma kinase fusions. For the first time, to our knowledge, the guideline includes recommendations regarding RET, MET, and NTRK alterations. Chemotherapy is still an option at most stages. Additional information is available at www.asco.org/thoracic-cancer-guidelines .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Self-citationOsimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Self-citationFerrell, B. R., Temel, J. S., Temin, S., Alesi, E. R., Balboni, T. A., Basch, E. M., Firn, J. I., Paice, J. A., Peppercorn, J. M., Phillips, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1474 · Cited by 2,117
Self-citationDoebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
Self-citationWu, Y.-L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Tsuji, F., Linke, R., Rosell, R., Corral, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30608-3 · Cited by 1,216
Self-citationPark, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30033-x · Cited by 1,183
Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D.-W., Mok, T., Polli, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027187 · Cited by 1,099
Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer
Wolf, J., Seto, T., Han, J.-Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Hida, T., de Jonge, M., Orlov, S. V., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002787 · Cited by 1,000
Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer
Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C.-H., Han, J.-Y., Lee, J.-S., Hochmair, M. J., Li, J. Y.-C., Chang, G.-C., Lee, K. H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810171 · Cited by 980
Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 946
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6706 · Cited by 912
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 911
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paik, P. K., Felip, E., Veillon, R., Sakai, H., Cortot, A. B., Garassino, M. C., Mazieres, J., Viteri, S., Senellart, H., Van Meerbeeck, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004407 · Cited by 870
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005653 · Cited by 828
Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., Chiari, R., Bearz, A., Lin, C.-C., Gadgeel, S. M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30649-1 · Cited by 791
Self-citationHan, J.-Y., Park, K., Kim, S.-W., Lee, D. H., Kim, H. Y., Kim, H. T., Ahn, M. J., Yun, T., Ahn, J. S., Suh, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8456 · Cited by 736
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Blayney, D. W., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., Lyman, G. H., Meropol, N. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2518 · Cited by 655
Hanna, N., Johnson, D., Temin, S., Baker, S., Brahmer, J., Ellis, P. M., Giaccone, G., Hesketh, P. J., Jaiyesimi, I., Leighl, N. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.6065 · Cited by 643
Self-citationShaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00488-x · Cited by 638
Self-citationAmerican Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Meropol, N. J., Schrag, D., Smith, T. J., Mulvey, T. M., Langdon, R. M., Blum, D., Ubel, P. A., & Schnipper, L. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1183 · Cited by 638
Patient-clinician communication: American Society of Clinical Oncology consensus guideline
Gilligan, T., Coyle, N., Frankel, R. M., Berry, D. L., Bohlke, K., Epstein, R. M., Finlay, E., Jackson, V. A., Lathan, C. S., Loprinzi, C. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2311 · Cited by 610
Nakagawa, K., Garon, E. B., Seto, T., Nishio, M., Ponce Aix, S., Paz-Ares, L., Chiu, C.-H., Park, K., Novello, S., Nadal, E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30634-5 · Cited by 603
Lee, C. K., Man, J., Lord, S., Cooper, W., Links, M., Gebski, V., Herbst, R. S., Gralla, R. J., Mok, T., & Yang, J. C.-H. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4427 · Cited by 598
Kim, D.-W., Tiseo, M., Ahn, M.-J., Reckamp, K. L., Hansen, K. H., Kim, S.-W., Huber, R. M., West, H. L., Groen, H. J. M., Hochmair, M. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.5904 · Cited by 581
Self-citationShaw, A. T., Kim, T. M., Crinò, L., Gridelli, C., Kiura, K., Liu, G., Novello, S., Bearz, A., Gautschi, O., Mok, T., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30339-x · Cited by 567
Self-citationDrilon, A., Siena, S., Dziadziuszko, R., Barlesi, F., Krebs, M. G., Shaw, A. T., de Braud, F., Rolfo, C., Ahn, M.-J., Wolf, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30690-4 · Cited by 528
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9123 · Cited by 500
Kalemkerian, G. P., Narula, N., Kennedy, E. B., Biermann, W. A., Donington, J., Leighl, N. B., Lew, M., Pantelas, J., Ramalingam, S. S., Reck, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7293 · Cited by 492
Self-citationHosomi, Y., Morita, S., Sugawara, S., Kato, T., Fukuhara, T., Gemma, A., Takahashi, K., Fujita, Y., Harada, T., Minato, K., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01488 · Cited by 481
Hanna, N. H., Schneider, B. J., Temin, S., Baker, S., Brahmer, J., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03022 · Cited by 456
Self-citationMok, T. S., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Lee, M., Linke, R., Rosell, R., Corral, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.7994 · Cited by 439
Self-citationShi, Y., Zhang, L., Liu, X., Zhou, C., Zhang, L., Zhang, S., Wang, D., Li, Q., Qin, S., Hu, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70355-3 · Cited by 422
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
Noronha, V., Patil, V. M., Joshi, A., Menon, N., Chougule, A., Mahajan, A., Janu, A., Purandare, N., Kumar, R., More, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01154 · Cited by 418
Cho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., Choi, Y. H., Ahn, M. S., Lee, M. H., Sun, J.-M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00931 · Cited by 358
Shaw, A. T., Solomon, B. J., Chiari, R., Riely, G. J., Besse, B., Soo, R. A., Kao, S., Lin, C.-C., Bauer, T. M., Clancy, J. S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30655-2 · Cited by 358
Self-citationWu, Y.-L., Yang, J. C.-H., Kim, D.-W., Lu, S., Zhou, J., Seto, T., Yang, J.-J., Yamamoto, N., Ahn, M.-J., Takahashi, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5587 · Cited by 326
Metastatic Pancreatic Cancer: ASCO Guideline Update
Sohal, D. P. S., Kennedy, E. B., Cinar, P., Conroy, T., Copur, M. S., Crane, C. H., Garrido-Laguna, I., Lau, M. W., Johnson, T., Krishnamurthi, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01364 · Cited by 307
Lim, S. M., Kim, H. R., Lee, J.-S., Lee, K. H., Lee, Y.-G., Min, Y. J., Cho, E. K., Lee, S. S., Kim, B.-S., Choi, M. Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3701 · Cited by 301
Shi, Y. K., Wang, L., Han, B. H., Li, W., Yu, P., Liu, Y. P., Ding, C. M., Song, X., Ma, Z. Y., Ren, X. L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx359 · Cited by 287
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
Yang, J. C.-H., Schuler, M., Popat, S., Miura, S., Heeke, S., Park, K., Märten, A., & Kim, E. S. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.126 · Cited by 274
Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
Streeter, S. B., Schwartzberg, L., Husain, N., & Johnsrud, M. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2011.000316 · Cited by 248
Peters, S., Stahel, R., Bubendorf, L., Bonomi, P., Villegas, A., Kowalski, D. M., Baik, C. S., Isla, D., Carpeno, J. D. C., Garrido, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1590 · Cited by 236
(2008) · Cited by 225
Moehler, M., Shitara, K., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., Liu, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2296 · Cited by 208
Landi, L., Chiari, R., Tiseo, M., D'Incà, F., Dazzi, C., Chella, A., Delmonte, A., Bonanno, L., Giannarelli, D., Cortinovis, D. L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0994 · Cited by 186
Shiffman, R. N., Michel, G., Rosenfeld, R. M., & Davidson, C. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000172 · Cited by 184
Cheng, Y., Murakami, H., Yang, P.-C., He, J., Nakagawa, K., Kang, J. H., Kim, J.-H., Wang, X., Enatsu, S., Puri, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9218 · Cited by 182
Yang, J. J., Zhou, Q., Yan, H. H., Zhang, X. C., Chen, H. J., Tu, H. Y., Wang, Z., Xu, C. R., Su, J., Wang, B. C., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.456 · Cited by 175
Nakagawa, K., Hida, T., Nokihara, H., Morise, M., Azuma, K., Kim, Y. H., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.11.025 · Cited by 149
BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer
Nguyen‐Ngoc, T., Bouchaab, H., Adjei, A. A., & Peters, S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000644 · Cited by 140
Michels, S. Y. F., Massutí, B., Schildhaus, H., Franklin, J. G., Sebastian, M., Felip, E., Grohé, C., Rodríguez‐Abreu, D., Abdulla, D. S. Y., Bischoff, H. G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.020 · Cited by 135
Self-citationGainor, J. F., Lee, K. H., Curigliano, G., Doebele, R. C., Kim, D., Baik, C. S., Tan, D. S.-W., Junior, G. L. L., Gadgeel, S. M., Cassier, P. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9008 · Cited by 112
Carter, C. A., Rajan, A., Keen, C., Szabo, E. M., Khozin, S., Thomas, A., Brzezniak, C. E., Guha, U., Doyle, L. A., Steinberg, S. M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw008 · Cited by 90
Subbiah, V., Gervais, R., Riely, G. J., Hollebecque, A., Blay, J., Felip, E., Schüler, M., Gonçalvès, A., Italiano, A., Keedy, V. L., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00266 · Cited by 85
Self-citationGainor, J. F., Curigliano, G., Kim, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9515 · Cited by 74
Furuya, N., Fukuhara, T., Saito, H., Watanabe, K., Sugawara, S., Iwasawa, S., Tsunezuka, Y., Yamaguchi, O., Okada, M., Yoshimori, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9006 · Cited by 59
Zhou, Q. H., Wu, Y.-L. L. C., Cheng, Y., Li, Y., Chen, G.-Q., Cui, J., Yang, N., Song, Y., Li, X., Lü, S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz260.002 · Cited by 55
Imai, H., Kaira, K., Suzuki, K., Anzai, M., Tsuda, T., Ishizuka, T., Kuwako, T., Naruse, I., Nemoto, K., Uchino, J., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.014 · Cited by 49
Cai, D., Hu, C., Li, L., Deng, S., Yang, J., Han‐Zhang, H., & Li, M. (2019) · Cancer Medicine · doi:10.1002/cam4.2682 · Cited by 41
An, C., Zhang, J., Chu, H., Gu, C., Xiao, F., Zhu, F., Lu, R., Shi, H., Zhang, H., & Yi, X. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0067-4 · Cited by 35
Ahn, M., Cho, J. H., Sun, J., Lee, S., Ahn, J. S., Park, K., Park, K. U., Kang, E. J., Choi, Y. H., Kim, K. H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9050 · Cited by 23
Cited by
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,392
Self-citationTreatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
Vogelbaum, M. A., Brown, P. D., Messersmith, H., Brastianos, P. K., Burri, S., Cahill, D., Dunn, I. F., Gaspar, L. E., Gatson, N. T. N., Gondi, V., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02314 · Cited by 832
Self-citationOsimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
Planchard, D., Jänne, P. A., Cheng, Y., Yang, J. C.-H., Yanagitani, N., Kim, S.-W., Sugawara, S., Yu, Y., Fan, Y., Geater, S. L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306434 · Cited by 740
Planchard, D., Besse, B., Groen, H. J. M., Hashemi, S. M. S., Mazieres, J., Kim, T. M., Quoix, E., Souquet, P.-J., Barlesi, F., Baik, C., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.011 · Cited by 272
Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
Mithoowani, H., & Febbraro, M. (2022) · Current Oncology · doi:10.3390/curroncol29030150 · Cited by 259
Metadata
- Authors
- Hanna, N. H., Robinson, A. G., Temin, S., Baker, S., Brahmer, J. R., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., Jaiyesimi, I., Johnson, D. H., Leighl, N. B., Moffitt, P. R., Phillips, T., Riely, G. J., Rosell, R., Schiller, J. H., Schneider, B. J., Singh, N., Spigel, D. R., Tashbar, J., & Masters, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2021-03-20
- Volume
- 39
- Issue
- 9
- Pages
- 1040-1091
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4252867417
- Cited by
- 300
- References
- 72
- FWCI
- 36.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.